What’s going on with Innocan Pharma?
Innocan Pharma Corp. (INNPF) stock was slightly lower after the Canadian company revealed that a recent study on mice found an extended presence of cannabidiol (CBD) in the bloodstream — for more than seven weeks after two injections. Shares of INNPF were trading 0.31% lower at $0.41 per share on Friday morning.
The company described the findings as “extremely encouraging” because CBD is typically present 24 hours in the bloodstream when introduced through other methods.
What does this mean for INNPF?
Innocan Pharma Ltd., a wholly owned subsidiary, has an exclusive research and license agreement with Yissum Research and Development Company, the commercial arm of The Hebrew University of Jerusalem, to design, prepare and…